Clene Inc.
CLNN
Rank in Stocks
#21814
Clene Inc. is a biopharmaceutical firm in the clinical development phase,... Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Share Price
$4.38
Last synced: 2026-11-09
Market Cap
$62.26M
Change (1 day)
10.89%
Change (1 year)
-54.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Clene Inc. (CLNN)
Category
Healthcare
EPS for Clene Inc. (CLNN)
EPS as of September 2026 TTM: $-2.40
According to Clene Inc.'s latest financial reports, its current EPS (TTM) is $-2.40. At the end of 2025 the company had an EPS of $-2.65, an increase over its 2024 EPS of $-5.67.
EPS history for Clene Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.40 | -9.43% |
| 2025 | $-2.65 | -53.26% |
| 2024 | $-5.67 | -39.87% |
| 2023 | $-9.43 | 101.07% |
| 2022 | $-4.69 | 48.42% |
| 2021 | $-3.16 | -42.65% |
| 2020 | $-5.51 | 17.48% |
| 2019 | $-4.69 | 5,175.59% |
| 2018 | $-0.09 | 11,012.50% |
| 2017 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -752.50% |
US
|
|
| $-7.07 | 194.58% |
US
|
|
| $-5.29 | 120.42% |
AU
|
|
| $12.88 | -636.67% |
BE
|
|
| $21.56 | -998.33% |
NL
|
Questions about Clene Inc.'s earnings per share (EPS)
What is Clene Inc.'s earnings per share (EPS)?
Clene Inc.'s earnings per share (EPS) over the last twelve months is $-2.40, as of Sep 2026.
What was Clene Inc.'s earnings per share (EPS) in 2025?
In 2025, Clene Inc.'s earnings per share (EPS) was $-2.65, compared with $-5.67 in 2024.
How has Clene Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Clene Inc.'s earnings per share (EPS) was highest in 2025 ($-2.65) and lowest in 2023 ($-9.43).
How does Clene Inc.'s earnings per share (EPS) compare with similar companies?
Clene Inc.'s earnings per share (EPS) ($-2.40) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.